PHOENIX–(BUSINESS WIRE)–OncoMyx Therapeutics, a privately-held oncolytic virus immunotherapy company, today announced the appointment of Robert Williamson as Chief Business and Chief Financial Officer. Mr. Williamson has more than two decades of experience in building, financing, and leading private and public biotechnology companies through critical phases of growth. At OncoMyx, Mr. Williamson will lead the business development and financing strategies to maximize the company’s pipeline of multi-armed myxoma immunotherapies for the treatment of solid tumors and hematological malignancies.Continue reading
Author Archive: AZBio
Hormone and gut bacteria link may guide better treatment for menopause symptoms
Arizona State University scientists Rosa Krajmalnik-Brown and Heather Bimonte-Nelson at the ASU Biodesign Institute have found that hormones and gut bacteria affect each other, leading to changes in metabolism and brain function. This relationship could be key for treating menopausal symptoms and improving women’s health.Continue reading
Aegis Consortium leaders envision a pandemic-free future
A new initiative seeks to unite global experts from universities, government agencies, nonprofits and industry to develop solutions to future pandemics.Continue reading
ASU researchers named senior members of the National Academy of Inventors
The National Academy of Inventors (NAI) has named Arizona State University Deputy Director Stephen Munk and Professor Bertram Jacobs to the February 2022 class of senior members.Continue reading
Symple Surgical Awarded SBIR Phase I Grant for Novel Radiometry‐Guided Ablation Catheter to Reliably Treat Barrett’s Esophagus
The National Institutes of Health Small Business Innovation Research Program Supports Symple Surgical’s Microwave Ablation TechnologyContinue reading
American Cancer Society Awards $16 Million in Grants to Establish Cancer Health Equity Research Centers
ATLANTA – Feb. 24, 2022 – The American Cancer Society has awarded over $16 million in grants to establish Cancer Health Equity Research Centers (CHERC) at Minority Serving Institutions (MSIs). The inaugural cohort of institutions includes the Arizona Board of Regents – University of Arizona; the University of Illinois at Chicago; Morehouse School of Medicine and Howard University. Each institution received a four-year grant of $4.08 million.Continue reading
Seven Arizona bioscience startups to watch in 2022
Metro Phoenix, Tucson firms to earn $30K through Flinn Foundation entrepreneurship programContinue reading
Panbela Therapeutics, Inc. to Acquire Cancer Prevention Pharmaceuticals, Inc.
- Creates late-stage, diversified pipeline that uses a multi-targeted approach to reset dysregulated biology to address considerable unmet needs
- Combined pipeline extends from pre-clinical to registration studies, with near-term clinical and regulatory milestones
- Acquired lead asset will begin a fully-funded registration trial anticipated to start by year-end
Breakthrough study uses genetic testing to evaluate risk of heart disease
(PHOENIX, Ariz. – Feb. 17, 2022) –Dignity Health in Arizona is launching the first research study in North America in which genetic testing is used to identify men and women at risk of developing heart disease based on the makeup of their DNA. If proven effective in clinical trials, this form of genetic testing may be adopted globally to prevent heart disease. Heart disease is the No. 1 killer in the world – in fact, half of Americans are expected to have at least one cardiac event in their lifetime. Continue reading
What Drives the Creation and Delivery of Cures and What Doesn’t
AZBio President & CEO, Joan Koerber-Walker, shared insights with Duane Schulthess, Managing Director of Vital Transformation on the the Vital Health Podcast. The popular podcast series has a global reach and features relaxed, one on one discussion with health care professionals, researchers, and regulators. Topics explore the implications of new medical procedures, technologies and policies as well as their impact on current clinical practices.